ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares closed down about 13% after the company announced a proposed public offering of its common stock yesterday. The biopharm company plans on selling $300 million worth of shares, with the sale managed by BofA Merril Lynch and P.P Morgan Securities LLC.  According to TipRanks’ statistics, out of the 3 analysts who have rated the company in the past 3 months, 2 gave a Buy rating while 1 remains on the sidelines. The average 12-month price target for the stock is $45.33, marking a 51% upside from current levels.

Cempra Inc (NASDAQ:CEMP) shares closed down on Wednesday at $24.74, down about 14% after yesterday’s news of a proposed public offering of $175 million worth of common stock. The company announced plans to use these proceeds to fund the commercial launch of antibiotic solithromycin in the U.S and R&D expenses. According to TipRanks’ statistics, out of the 9 analysts who have rated the company in the past 3 moths, 8 gave a Buy rating while 1 remains on the sidelines. The average 12-month price target for the stock is $49.67, marking a 60% upside from current levels.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) is plunging close to 19% after analyst Brian Abrahams of Jefferies downgraded to stock from Buy to Hold and lowered his price target to $14 from $20. The analyst attributes his downgrade to “updated timelines skewing towards higher-risk selinexor readouts in 2016,” stating that safety data will give selinexor “slightly more of a niche role.” According to TipRanks’ statistics, out of the 3 analysts who have rated the company in the past 3 months, 2 gave a Buy rating while 1 remains on the sidelines. The average 12-month price target for the stock is $18, marking a 56% upside from current levels.